[
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=a355b31811babb852fbc2a2448cc09983181c88105661a0f37b7deb3e2750850",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745512260,
      "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "id": 134071434,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=a355b31811babb852fbc2a2448cc09983181c88105661a0f37b7deb3e2750850"
    }
  },
  {
    "ts": null,
    "headline": "This veteran investor is known for spotting winning stocks. Here’s why he’s all-in on Nvidia and Eli Lilly.",
    "summary": "This veteran investor is known for spotting winning stocks. Here’s why he’s all-in on Nvidia and Eli Lilly.",
    "url": "https://finnhub.io/api/news?id=d16ac7bae85c2258f323ffcd267ce17c0ee13084fddf9b475b73a1a0db63fd51",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745510820,
      "headline": "This veteran investor is known for spotting winning stocks. Here’s why he’s all-in on Nvidia and Eli Lilly.",
      "id": 134071054,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "This veteran investor is known for spotting winning stocks. Here’s why he’s all-in on Nvidia and Eli Lilly.",
      "url": "https://finnhub.io/api/news?id=d16ac7bae85c2258f323ffcd267ce17c0ee13084fddf9b475b73a1a0db63fd51"
    }
  },
  {
    "ts": null,
    "headline": "PFE vs. LLY: Which Stock Should Value Investors Buy Now?",
    "summary": "PFE vs. LLY: Which Stock Is the Better Value Option?",
    "url": "https://finnhub.io/api/news?id=dd4f5bf2949376b74e18e18ab362c38551f523b57f61a788381b9b82c97e3d90",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745509205,
      "headline": "PFE vs. LLY: Which Stock Should Value Investors Buy Now?",
      "id": 134067371,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "PFE vs. LLY: Which Stock Is the Better Value Option?",
      "url": "https://finnhub.io/api/news?id=dd4f5bf2949376b74e18e18ab362c38551f523b57f61a788381b9b82c97e3d90"
    }
  },
  {
    "ts": null,
    "headline": "Roche's Q1 Sales Increase Y/Y on Solid Performance of Key Drugs",
    "summary": "RHHBY records impressive first-quarter 2025 performance on the back of strong demand for key drugs. The company confirms 2025 guidance.",
    "url": "https://finnhub.io/api/news?id=241fe74daef1842c575aa0585541a6c1275f4c6b00047a69bbe39823b2102056",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745509020,
      "headline": "Roche's Q1 Sales Increase Y/Y on Solid Performance of Key Drugs",
      "id": 134067372,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "RHHBY records impressive first-quarter 2025 performance on the back of strong demand for key drugs. The company confirms 2025 guidance.",
      "url": "https://finnhub.io/api/news?id=241fe74daef1842c575aa0585541a6c1275f4c6b00047a69bbe39823b2102056"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Plunges 17% in a Month: Buy, Sell or Hold the Stock?",
    "summary": "Despite the current downward trend, long-term investors may stay invested in NVO stock due to strong demand for its GLP-1 drugs.",
    "url": "https://finnhub.io/api/news?id=36d53f1ab1a504c4e85892ab3f5dd12ad5a85ced68fd4adc8a66d7ef6491c7c0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745507880,
      "headline": "Novo Nordisk Plunges 17% in a Month: Buy, Sell or Hold the Stock?",
      "id": 134067373,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Despite the current downward trend, long-term investors may stay invested in NVO stock due to strong demand for its GLP-1 drugs.",
      "url": "https://finnhub.io/api/news?id=36d53f1ab1a504c4e85892ab3f5dd12ad5a85ced68fd4adc8a66d7ef6491c7c0"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release",
    "summary": "Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=ff8a0536bc458d0e4d27e9bb694fc33c367c77c1fecded6125cc1725794c5957",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745503316,
      "headline": "Eli Lilly (LLY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release",
      "id": 134067374,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=ff8a0536bc458d0e4d27e9bb694fc33c367c77c1fecded6125cc1725794c5957"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Stock Soars on Weight-Loss News. Why It’s Bad for Novo Nordisk.",
    "summary": "Eli Lilly Stock Soars on Weight-Loss News. Why It’s Bad for Novo Nordisk.",
    "url": "https://finnhub.io/api/news?id=0180371b60eb8a5d235b563fb943a4fdbd8aaafdfc0ee44a494acdac9950afd9",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745489460,
      "headline": "Eli Lilly Stock Soars on Weight-Loss News. Why It’s Bad for Novo Nordisk.",
      "id": 134146413,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly Stock Soars on Weight-Loss News. Why It’s Bad for Novo Nordisk.",
      "url": "https://finnhub.io/api/news?id=0180371b60eb8a5d235b563fb943a4fdbd8aaafdfc0ee44a494acdac9950afd9"
    }
  },
  {
    "ts": null,
    "headline": "Aristotle Focus Growth Q1 2025 Commentary",
    "summary": "For Q1 2025, Aristotle Atlanticâs Focus Growth Composite posted a total return of -8.47% gross of fees, outperforming the -9.97% total return of the Russell 1000 Growth Index.",
    "url": "https://finnhub.io/api/news?id=caecf4cef5701c9a9b3d697e6917003e23a0ffa78a6367195aeb2a3738fd16f4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745487900,
      "headline": "Aristotle Focus Growth Q1 2025 Commentary",
      "id": 134061049,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1316412910/image_1316412910.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "For Q1 2025, Aristotle Atlanticâs Focus Growth Composite posted a total return of -8.47% gross of fees, outperforming the -9.97% total return of the Russell 1000 Growth Index.",
      "url": "https://finnhub.io/api/news?id=caecf4cef5701c9a9b3d697e6917003e23a0ffa78a6367195aeb2a3738fd16f4"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Just Proved The Bears Wrong Again",
    "summary": "Johnson & Johnson has started 2025 better than I expected, even with the long-running talc saga. Find out why I remain bullish on JNJ stock.",
    "url": "https://finnhub.io/api/news?id=57aa4cff71446c393dbf92bb5ecae722b966749d477e71cda454ed310acd9580",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745480800,
      "headline": "Johnson & Johnson Just Proved The Bears Wrong Again",
      "id": 134058686,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1146642361/image_1146642361.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Johnson & Johnson has started 2025 better than I expected, even with the long-running talc saga. Find out why I remain bullish on JNJ stock.",
      "url": "https://finnhub.io/api/news?id=57aa4cff71446c393dbf92bb5ecae722b966749d477e71cda454ed310acd9580"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer Calls Eli Lilly and Company (LLY) a ‘Game Changer’ After Obesity Pill Trial Success",
    "summary": "We recently published a list of Jim Cramer Says Trump’s Fed Chair Tussle Is Like “The Godfather” & Discusses These 10 Stocks. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other stocks that Jim Cramer discussed. In a recent appearance on CNBC’s Squawk on […]",
    "url": "https://finnhub.io/api/news?id=21090825e040c19c28ce47e5eca6201fc737bfd3f1fbfeba3cb9bf5524c051fa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745457742,
      "headline": "Jim Cramer Calls Eli Lilly and Company (LLY) a ‘Game Changer’ After Obesity Pill Trial Success",
      "id": 134059253,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published a list of Jim Cramer Says Trump’s Fed Chair Tussle Is Like “The Godfather” & Discusses These 10 Stocks. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other stocks that Jim Cramer discussed. In a recent appearance on CNBC’s Squawk on […]",
      "url": "https://finnhub.io/api/news?id=21090825e040c19c28ce47e5eca6201fc737bfd3f1fbfeba3cb9bf5524c051fa"
    }
  }
]